Is Primary Retroperitoneal Lymph Node Dissection the Way Forward for Patients with Testicular Seminoma and Limited Retroperitoneal Metastases? - Beyond the Abstract ...

Therapeutic Advances in Metastatic Prostate Cancer: A Journey from Standard of Care to New Emerging Treatment. December 12, 2025 Predicting Toxicities and Survival Outcomes in De Novo Metastatic ...

Robotic/laparoscopic prolapse repair and the role of hysteropexy: A urology perspective, "Beyond the Abstract," by Daniel S. Elliott, MD ...

ASCO 2025 Press Releases Johnson & Johnson Leads with First PARP Inhibitor Combo to Improve Efficacy in Patients with HRR-altered mCSPC ImmunityBio Receives FDA Expanded Access Authorization for ...

Patient Out-of-Pocket Costs for Guideline-Recommended Treatments for Erectile Dysfunction: A Medicare Cost Modeling Analysis - Beyond the Abstract ...

Robotic versus Open Cystectomy with Ileal Conduit for the Management of Neurogenic Bladder: A Comparative Study - Beyond the Abstract ...

Varicocele and Sperm DNA Fragmentation: New Evidence with Implications for Clinical Practice - Beyond the Abstract ...

(UroToday.com) The 2025 SUO annual meeting featured the Huggins Medal Lecture and presentation by this year’s recipient, Dr. Peter Carroll, discussing “What I did and What I am Doing”. Important ...

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...

Amy Pearlman discusses penile rehabilitation strategies following prostate cancer treatment. Dr. Pearlman shares her expertise on vacuum pump therapy as a crucial component of penile rehabilitation.

Read the Full Video Transcript Rashid Sayyid: Hello, everyone, and thank you for joining us today in this UroToday recording. I'm Rashid Sayyid, robotic urology and oncology fellow at USC, and I'm ...

Giulia Marvaso discusses the RADIOSA trial, a phase II randomized study comparing SBRT alone versus SBRT with short-course hormonal therapy for oligorecurrent prostate cancer. The trial includes 102 ...